Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.
The information provided here is drawn from ClinicalTrials.gov. If you do not find a satisfactory expanded access program here, please search in our COVID Company Directory. Some companies consider expanded access requests for single patients, even if they do not show an active expanded access listing in this database. Please contact the company directly to explore the possibility of expanded access.
Emergency INDs
To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.
Search Tips
To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.
Displaying 50 of 140Istanbul Medipol University Hospital
In this study, providing access to physiotherapy applications by telerehabilitationmethod and the effectiveness of this application will be examined for patients who haveundergone lung surgery in the early postoperative period during the pandemic process inwhich social isolation continues.
National Cancer Institute (NCI)
This is a phase I trial followed by a phase II randomized trial. The purpose of phase Istudy is the feasibility of treating patients with acute respiratory distress syndrome(ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stemcells (MSC). The purpose of the phase II trial is to compare the effect of MSC withstandard of care in these patients. MSCs are a type of stem cells that can be taken fromumbilical cord blood and grown into many different cell types that can be used to treatcancer and other diseases. The MSCs being used for infusion in this trial are collectedfrom healthy, unrelated donors and are stored and grown in a laboratory. Giving MSCinfusions may help control the symptoms of COVID-19 related ARDS.
ClinAmygate
The study explore the relationship between COVID-19 and the induction of autoimmunediseases.
Assistance Publique - Hôpitaux de Paris
The purpose of the study is to evaluate the presence of early vascular aging 6 months and12 months after COVID-19 infection.
Karolinska Institutet
Prospective, single center, randomized, open label, parallel group, 2-arm study assessingthe clinical benefit in term of enhancement of overall response rate of Isatuximab incombination with CellProtect as compared to Isatuximab for the treatment of patients withnewly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) asmaintenance after SCT.
National Cancer Institute (NCI)
The study investigates how the COVID-19 pandemic has impacted the psychological,financial, physical, and social well-being of adolescent and young adult (AYA) cancerpatients and survivors. AYA cancer survivors have inferior long-term survival compared tothe general population, and the negative impact of the global COVID-19 pandemic may beeven higher in this vulnerable group. The information gained from this study may providean opportunity to determine the self-reported COVID-19 specific psychological distress inAYA cancer survivors, and may lead to the development of a targeted intervention toimprove physical and psychosocial health for AYA cancer patients and survivors.
Wuhan Union Hospital, China
The intent of this study was to examine the health status of individuals who had beenconfirmed with COVID-19 in the year after their recovery. Parameters studied includedserum levels of SARS coronavirus 2 (SARS-CoV 2) IgG antibody, SARS-CoV-2 nucleic acidtest, hematology indicators (blood routine, liver function, kidney function, myocardialenzymes, coagulation function, etc), lung function test, imaging data and airwaymicrobiota data. In addition, we explored the systematic Immune & Inflammation in some ofthe individuals recovering from COVID-19.
Baylx Inc.
This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part isan open-label, single-arm, dose-escalating study to evaluate the safety and explore thedose limiting toxicity and maximum tolerated dose of a human umbilical cord derivedmesenchymal stem cell product (BX-U001) in severe COVID-19 pneumonia patients with acuterespiratory distress syndrome (ARDS). Qualified subjects after the screening will bedivided into low, medium, or high dose groups to receive a single intravenous infusion ofBX-U001 at the dose of 0.5×10^6, 1.0×10^6, or 1.5×10^6 cells/kg of body weight,respectively. The Phase 2a part is a randomized, placebo-controlled, double-blindclinical trial examining the safety and biological effects of BX-U001 at the appropriatedose selected from phase 1 for severe COVID-19 pneumonia patients with the sameinclusion/exclusion criteria as the phase 1 part.
University of Giessen
By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients withpneumonia in Wuhan, China. In the following weeks and months the virus spread globally,having a tremendous impact on global health and economy. To date, no vaccine or therapyis available. Severe courses of the infection not only affect the lungs, but also otherorgans like the heart, kidney, or liver. The lack of preexisting immunity might at leastpartially explain the affection of extra pulmonary organs not yet seen in infections dueto other respiratory viruses. In this observational investigation the study group willfollow up on patients that have been hospitalized due to a SARS-CoV-2 infection, andmonitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system.Our that in some patients, organ damage will persist and require long-term medical care.
King's College London
The aims of the BIBS StudyThe Brain Imaging in Babies study (BIBS) aims to improve understanding of how a baby'sbrain develops from before birth, up until 3-4 years of age. Working with children from avariety of backgrounds and communities, the investigators use a combination ofstate-of-the-art diagnostic tools such as MRI scans alongside traditional behaviouralassessments to capture the earliest information on infant brain development.The focus of the BIBS studyMRI scanning is a safe way of producing detailed images using strong magnetic fields andradio waves. It does not use X-ray. Along with learning more about brain development ingeneral, the investigators also try to identify features that may in future help predictwhether a child will or will not develop traits of conditions such as Autism SpectrumDisorder (ASD) or Attention Deficit Hyperactivity Disorder (ADHD). Long-term, this mayhelp target useful interventions early on, helping children who are most in need.Since COVID-19 arrived in the United Kingdom (U.K.) in 2020, the investigators have beengiven ethical approval to include testing for this infection in the mothers and childrenparticipating in the study. This may provide an opportunity to better understand howmother and baby respond to infections. The investigators particularly welcome mothers whohave had a positive COVID-19 test during their pregnancy to join the study.